Causal effect of gut microbiota on juvenile idiopathic arthritis: A two-sample Mendelian a randomization study

Lian Zhang1, Zhihua Yang2, LuLu Zhang1

  • 1Shenzhen Children's Hospital, Shenzhen, China.

Insights

This study used Mendelian randomization to investigate the gut microbiome

Area of Science:

  • Microbiome research
  • Immunology
  • Genetics

Background:

  • Juvenile idiopathic arthritis (JIA) is a complex autoimmune disease.
  • The gut microbiome's role in JIA pathogenesis is increasingly recognized but not fully understood.
  • Causal links between specific gut bacteria and JIA risk require elucidation.

Purpose of the Study:

  • To investigate the causal relationship between gut microbiome composition and juvenile idiopathic arthritis (JIA).
  • To identify specific bacterial taxa that may causally influence JIA risk.
  • To explore potential therapeutic targets within the gut microbiome for JIA prevention and treatment.

Main Methods:

  • Two-sample Mendelian randomization (MR) study design.
  • Utilized publicly available genome-wide association study (GWAS) summary data for gut flora (MiBioGen) and JIA (NHGRI-EBI).
  • Employed inverse variance weighting (IVW) as the primary analysis method, with sensitivity analyses and reverse MR to assess causality and robustness.

Main Results:

  • Identified four bacterial taxa potentially causally associated with JIA risk.
  • Olsenella and Rikenellaceae (RC9gutgroup) showed a positive association with JIA risk.
  • Catenibacterium and Holdemania exhibited a negative association with JIA risk, suggesting a protective effect, though these findings require cautious interpretation due to sensitivity analysis results.
  • Reverse MR analysis found no evidence of reverse causality.

Conclusions:

  • This study provides evidence for a causal relationship between specific gut bacteria and juvenile idiopathic arthritis.
  • Olsenella and Rikenellaceae may be risk factors, while Catenibacterium and Holdemania might offer protection against JIA.
  • Modulating gut microbiome dysbiosis presents a novel therapeutic strategy for JIA.